Company: SHPH
Filing Date: 2025-12-11
Form Type: S-1/A
Source: 0001493152-25-027310
Chunk: 13

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-12-11
Form: S-1/A
Chunk 13
---
 under the Securities Act).

<div align='center'>LEGAL MATTERS</div>

The validity of the shares of common stock offered in this prospectus has been passed upon for us by Sullivan & Worcester LLP, New York, New York.

<div align='center'>EXPERTS</div>

The consolidated financial statements of Shuttle Pharmaceuticals Holdings, Inc. as of and for the years ended December 31, 2024 and 2023 incorporated by reference in this prospectus and in the registration statement of which this prospectus forms a part, have been so incorporated in reliance on the report of Forvis Mazars, LLP, an independent registered public accounting firm. Such consolidated financial statements have been incorporated herein in reliance upon such report given on the authority of such firm as experts in accounting and auditing. The report of Forvis Mazars, LLP contains an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern.

| 9 |

<div align='center'>INFORMATION INCORPORATED BY REFERENCE</div>

The SEC allows us to “incorporate by reference” information that we file with them. Incorporation by reference allows us to disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We filed a registration statement on Form S-1 under the Securities Act with the SEC with respect to the securities being offered pursuant to this prospectus. This prospectus omits certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits and schedules attached to the registration statement and the information incorporated by reference, for further information about us and the securities being offered pursuant to this prospectus. The documents we are incorporating by reference into this prospectus are:

| ● 
 ● | Our                                                                                                                                  
 Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 26, 2025;                     
 Our                                                                                                                                  
 Quarterly Reports on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 8, 2025, for the quarterly   
 period ended June 30, 2025, filed with the SEC on August 13, 2025, and for the quarterly period ended September 30, 2025, filed with 
 the SEC on November 13,